Abstract 1443P
Background
Hypertension is a common adverse drug reaction of using angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as bevacizumab or ramucirumab. Moreover, angiogenesis inhibitor-induced hypertension is associated with improved clinical outcomes in various cancers. Here, we retrospectively analyzed these data from FRUTIGA to evaluate whether clinical outcomes were associated with fruquintinib-induced hypertension in advanced G/GEJ adenocarcinoma patients treated with fruquintinib plus paclitaxel.
Methods
FRUTIGA was a randomized, double-blind, placebo-controlled phase 3 study. The treatment arm was given fruquintinib 4 mg orally, once daily for 3 weeks followed by 1 week off, plus paclitaxel 80 mg/m2 intravenously on days 1/8/15 per cycle. Post hoc analyses were conducted in the treatment arm.
Results
351 patients were randomized to fruquintinib plus paclitaxel treatment arm. Among these patients, 59 (16.8%) experienced fruquintinib-induced hypertension. 23 (6.6%) experienced grade 3 or more fruquintinib-induced hypertension. No patient permanently discontinued due to hypertension. These patients had a better clinical outcome than those with no occurrence of fruquintinib-induced hypertension, with higher objective response rates (ORR) of 57.6% (95% CI 44.1%-70.4%) versus 39.4% (95% CI 33.7%-45.2%) (p=0.0136). Progression-free survival (PFS) and overall survival (OS) were 8.08 months (95% CI 6.4-8.3) (p=0.0003) and 11.80 months (95% CI 9.3-16.2) (p=0.0157) in the fruquintinib-induced hypertension group, versus 4.63 months (95% CI 4.6-5.9) and 9.36 months (95% CI 8.4-10.4) in no fruquintinib-induced hypertension group, respectively.
Conclusions
Fruquintinib-induced hypertension was associated with higher ORR, longer PFS and OS in advanced G/GEJ adenocarcinoma patients. The fruquintinib-induced hypertension could potentially be predictive of clinical outcomes for pts with treatment with fruquintinib plus paclitaxel.
Clinical trial identification
NCT03223376.
Editorial acknowledgement
Legal entity responsible for the study
Hutchmed Limited.
Funding
The National Science and Technology Major Project (project no. 2019ZX09301012), the Science and Technology Commission of Shanghai Municipality (Science, Technology and Innovation Action Plan, project no. 17431900100) and Hutchmed Limited.
Disclosure
Q. Liu, S. Fan: Financial Interests, Personal, Full or part-time Employment: Hutchmed Limited. All other authors have declared no conflicts of interest.
Resources from the same session
1937P - Clinical characteristics and prognosis of pediatric patients with papillary thyroid carcinoma
Presenter: Junko Akaishi
Session: Poster session 18
1938P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Poster session 18
1939P - BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis
Presenter: Sima Kumari
Session: Poster session 18
1940TiP - Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
Presenter: Alejandro Garcia Alvarez
Session: Poster session 18
1941TiP - Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe)
Presenter: Claudia Leli
Session: Poster session 18
1924P - Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study
Presenter: Daisuke Hazama
Session: Poster session 18
1923P - Real-world management and outcome of thymic carcinomas in a tertiary German center
Presenter: Antonia Margineanu
Session: Poster session 18
1922P - Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Presenter: Iacopo Petrini
Session: Poster session 18
1921P - Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab
Presenter: Angelica Rigutto
Session: Poster session 18
1920P - Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Presenter: Akiko Tateishi
Session: Poster session 18